
Dec 23 (Reuters) - Invivyd Inc IVVD.O:
INVIVYD ANNOUNCES INITIATION OF DECLARATION CLINICAL TRIAL, A PHASE 3 PLACEBO-CONTROLLED PIVOTAL STUDY OF VYD2311, A VACCINE-ALTERNATIVE ANTIBODY TO PREVENT COVID
INVIVYD INC - TOP-LINE DATA EXPECTED MID-2026
INVIVYD INC - TRIAL TO ENROLL 1770 PARTICIPANTS FOR COVID INCIDENCE REDUCTION